Capricor Therapeutics, Inc. (CAPR) Stock Price & Analysis

Capricor Therapeutics, Inc. (CAPR) closed at USD 6.13 on Thursday, October 22, 2026, up 4.25% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 6.13; the Oct 22, 2026 session ranged USD 5.8–6.35 on volume of 2,748,488 shares. Market capitalization is —, with a 52-week range of USD 2.96–40.37 (NMS). Source: Nexqual, retrieved October 23, 2026 at 09:49 UTC.

Also available as compact Markdown for AI agents: nexqual.com/CAPR.md

Key facts (CAPR)

• Insider open-market sales, last ~7 months: 6 Form 4 filings, $3.1M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Hold (mean 2.50 on a 1–5 scale) (10 analysts), mean target USD 27 (range 7–54).
• Total return with dividends: 1Y +0.0% vs S&P 500 +14.9%; 5Y +60.5% vs S&P 500 +80.3%.
• Next earnings: 2026-11-10, EPS estimate USD -0.41, revenue estimate $10.4M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CAPR)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (CAPR)

Insider sales (SEC Form 4, open-market, last ~7 months) (CAPR)

6 of 6 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (CAPR)

Consensus Hold (mean 2.50 on a 1–5 scale), 10 analysts; mean target USD 27 (low 7, high 54).

Rating changes, last 120 days:

Total return (dividends reinvested) (CAPR)

CAPR suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 17, 2026.

CAPR company outlook (results filed Aug 13, 2026)

• “This outlook excludes any potential revenue from product sales, the potential monetization of a Priority Review Voucher, if received, or other non-operating sources of capital.”

Quoted word-for-word from the SEC 8-K results press release.

CAPR analyst estimates and revisions

CAPR options: expected move

Options price a move of about ±38.1% (±$2.33) by Nov 13, 2026, which includes earnings on Nov 10, 2026. Over the last 8 reports the stock moved ±15.3% on average.

30-day implied volatility 347.6% vs 93.2% realized over the last 30 trading days. Put/call ratio (volume) 2.96. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 09:49 UTC)

Technical Analysis (CAPR)

Nexqual's technical model rates CAPR "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:49 UTC.

Analyst Ratings (CAPR)

Wall Street analysts rate CAPR "Hold" based on 10 analysts, with a mean price target of USD 27 (range USD 7–54), per Nexqual as of October 23, 2026 at 09:49 UTC.

Earnings (CAPR)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 09:49 UTC.

Financials & Fundamentals (CAPR)

Source: Nexqual, October 23, 2026 at 09:49 UTC.

Ownership (CAPR)

Source: Nexqual, October 23, 2026 at 09:49 UTC.

Leadership (CAPR)

Capricor Therapeutics, Inc. is led by Linda Marbán, Co-Founder, President, CEO & Director, per Nexqual as of October 23, 2026 at 09:49 UTC.

Major Backers & Investors (CAPR)

Notable institutional backers of Capricor Therapeutics, Inc. include Tang Capital Management, LLC, Montanova Capital LLC, Goldman Sachs, according to Nexqual as of October 23, 2026 at 09:49 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 09:49 UTC.

From Capricor Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-17)

Key Strengths & Strategy (as disclosed to the SEC)

• Biologics License Application: In late 2024, we completed our submission of a BLA to the FDA seeking approval of Deramiocel for the treatment of Duchenne muscular dystrophy.
• Following a Type A meeting with the FDA in August 2025, we aligned with the Agency on a regulatory path forward to address the CRL, including the submission of additional clinical data from the Phase 3 HOPE-3 trial.
• Exosome Platform: Engineered Exosome-Based Vaccines: The StealthX™ vaccine is a proprietary vaccine developed internally by Capricor utilizing exosomes that were engineered to express either spike or nucleocapsid proteins on the surface.
• In mid-2025, the FDA completed its Pre-License Inspection ("PLI") of this facility in connection with our Biologics License Application for Deramiocel.

Partnerships

• On January 4, 2010, Capricor entered into an Exclusive License Agreement with CSMC (the "Original CSMC License Agreement"), for certain intellectual property related to its CDC technology.
• On May 5, 2014, Capricor entered into an Exclusive License Agreement with CSMC (the "Exosomes License Agreement"), for certain intellectual property rights related to CDC-derived exosomes technology.

Legal & Regulatory Risks (Item 1A, quoted)

• The biopharmaceutical industry is subject to extensive regulatory obligations and policies that may be subject to significant and abrupt change, including due to judicial challenges, election cycles, and resulting regulatory updates and changes in policy priorities.
• The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, interim results of a clinical trial do not necessarily predict final results, and the results of our clinical trials may not satisfy the requirements of the FDA or comparable foreign regulatory authorities.
• The regulatory pathway for COVID-19 or other infectious disease vaccines is continually evolving and may result in unexpected or unforeseen challenges.
• Any drugs we develop may become subject to unfavorable pricing regulations, third-party coverage, and reimbursement practices or healthcare reform initiatives, thereby harming our future business prospects.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:49 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt